A TriNetX study of 4,253 matched patients per group, shown at ACG 2026, found roughly half the MACE risk at one year with resmetirom. Retrospective data, so no causation.
Recap by typeshit. Full story at HCPLive.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Challenge 3 asks entrants to design a protein that activates the receptor semaglutide and tirzepatide target in diabetes and obesity treatment.
NexLife checked all-in prices at 21 telehealth programs in early October. Compounded semaglutide came in at a $175 median, with a $79 sale price at the low end.
Loading…